Publications by authors named "Kerry J Williams"
Article Synopsis
- UCN-01 (7-hydroxystaurosporine) is a protein kinase inhibitor that shows promise when combined with irinotecan in treating patients with resistant solid tumors, as demonstrated in a Phase I study.
- The study determined the maximum-tolerated dose (MTD) and found that the treatment had some serious side effects like grade 3 diarrhea and dyspnea, but overall showed manageable toxicity levels and effective pharmacokinetic properties.
- Notable outcomes included partial tumor responses in patients with specific breast cancer types and a significant number of patients maintaining stable disease for as long as 30 weeks, prompting further investigation of the UCN-01 and irinotecan combination, especially in triple-negative breast cancer (
Background: Only recently has a standard chemotherapy regimen, gemcitabine plus cisplatin, been established for advanced biliary tract cancers (BTCs) based on a phase III randomized study. The aim of this phase II single-institution trial was to assess the efficacy and safety of gemcitabine combined with carboplatin in the first-line treatment of patients with advanced BTCs.
Methods: Patients with histologically proven BTCs, including cholangiocarcinoma or gallbladder and ampullary carcinomas, were treated with a maximum of nine cycles of intravenous (i.
The tumor biology targeted therapies have improved outcomes in colorectal cancer (CRC). The epidermal growth factor receptor (EGFR) inhibitors represent one of these successful strategies. EGFR is frequently overexpressed in CRCs and associated with a malignant phenotype.
View Article and Find Full Text PDF